Sentence examples for multiple sclerosis clinical from inspiring English sources

Mrs. Sammarco, 30, is a family nurse practitioner and staff associate in neurology at NewYork Presbyterian Hospital/Weill Cornell Medical Center, in the multiple sclerosis clinical care and research center.

Historically, multiple sclerosis clinical trials have lacked sensitive, vision-specific outcome measures.

Electrophysiological measures of visual pathway integrity have had increasing roles in the investigation of vision in optic neuritis and multiple sclerosis clinical trials.

Ideally, visual measures used in multiple sclerosis clinical trials should be standardized, reliable, practical, tolerated by study participants, and applicable for both adult and paediatric populations.

Indeed, the median times from multiple sclerosis clinical onset to DSS 3 significantly decreased as age of multiple sclerosis onset increased.

Based on these observations, LCLA shows promise as a vision-related outcome for multiple sclerosis clinical trials and as an additional component test for the MSFC.

The use of therapies carrying potential serious risks is justified in patients who cannot be treated effectively with safe first-line therapies, but probably not in the average relapsing remitting multiple sclerosis or clinical isolated syndrome patient.

The presented approach might be useful in both, research as well as clinical routine, for automated segmentation and volume quantification of subcortical brain structures in order to increase confidence in the diagnosis of neuro-degenerative disorders, such as Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, or clinical applications for other neurologic and psychiatric diseases.

An international group of over 60 investigators in multiple sclerosis, neuro-ophthalmology, clinical trial design, and evaluation of clinical outcome measures from Europe, North America, Asia, and Australia met on 21 23 November 2013 in Dublin, Ireland (see Supplementary material for a list of attendees).

Although it is logical that definitive evaluation of new therapies should be based on clinically meaningful outcomes, there are major difficulties to overcome when conducting treatment trials in multiple sclerosis (MS) with clinical endpoints such as relapse rate or progression in disability.

The objective of this study was to investigate prevalence of MAP infection in association with Multiple Sclerosis (MS) using clinical specimen from patients and controls.